ChromaDex Corporation (NASDAQ:CDXC) an innovator of proprietary
health, wellness and nutritional ingredients that creates
science-based solutions for dietary supplement, food and beverage,
skin care, sports nutrition, and pharmaceutical products, announced
today that University of Iowa researchers have published a study in
the prestigious Journal of the International Association for the
Study of Pain (PAIN) showing that NIAGEN® Nicotinamide Riboside
(NR) ameliorates chemotherapy-induced peripheral neuropathy (CIPN)
in an animal model. Results from this study suggest that NR may be
an effective therapy in relieving chemotherapy induced peripheral
neuropathy (CIPN) in humans. Access to the study was made
available online on February 11, 2017.
Currently, the American Society for Clinical
Oncology considers the development of adjunctive therapy for the
prevention and relief of CIPN as essential for patient care. This
study provides an important proof of concept for the use of NR as a
novel therapeutic approach in filling the unmet need for treatments
that alleviate CIPN.
ChromaDex CEO and co-founder, Frank Jaksch, Jr.
stated, “This is another well-designed study that reinforces the
role of NR in neuronal protection. These results are
particularly important given that this research may contribute to
the discovery of a new therapeutic option for a significantly
underserved patient population.”
Led by Dr. Donna Hammond, Ph.D., the
research team at the University of Iowa demonstrated that treatment
with NR increased blood levels of nicotinamide adenine
dinucleotide (NAD+) by 50 percent after three weeks of daily
administration. NR was able to prevent the development of
tactile hypersensitivity induced by the chemotherapeutic paclitaxel
and reverse well-established tactile hypersensitivity, while also
blunting escape/avoidance behaviors. Furthermore, the prophylactic
effect was sustained for at least two weeks after treatment with NR
ceased.
Dr. Marta Hamity, Ph.D., the lead study author,
indicated that the team embarked on the study based on evidence
that suggested that increasing levels of NAD+ in the cells may
protect against neuronal injury. The study used female
Sprague-Dawley rats, clinically relevant doses of paclitaxel and
incorporated measures that quantify the impact of CIPN on quality
of life.
“This is significant because the pain associated
with CIPN can increase as the [chemotherapy] dose escalates, and at
times it reaches a point where the patient is no longer able to
tolerate the effective doses,” explained Hammond. “The American
Society of Clinical Oncology has issued a position paper that there
is an unmet need for treatments that can alleviate CIPN,” stated
Hammond. “This study has provided positive data which is
particularly exciting considering the unmet need for therapies in
this area. We believe that further development of NR as a therapy
for CIPN is warranted.”
NR has been the subject of nearly 200
peer-reviewed journal publications and is currently at the center
of over 100 collaborative studies between ChromaDex and leading
universities and research institutions around the world such as the
National Institute of Aging, MIT and the Scripps Research Institute
representing an estimated $40-50 million in NR research.
In November, 2016 ChromaDex announced that it
met with FDA to gain Agency guidance on the requirements needed to
successfully file an Investigational New Drug (IND) application to
initiate a Phase I/II clinical trial in patients with Cockayne
Syndrome. Jaksch commented, “ChromaDex is working towards
completing IND-enabling preclinical studies for Cockayne Syndrome
and filing that IND sometime in 2017.”
ChromaDex, being publicly traded on NASDAQ,
gives the public an opportunity for investing in the business of
science-based technologies for healthy aging and longevity. To
date, ChromaDex has invested millions in safety, toxicology and
human clinical trials on NR. Most of ChromaDex’s recent revenue
growth has come from its proprietary ingredients, in particular
NIAGEN®.
ChromaDex’s NIAGEN® is the only commercially
available form of NR and is supported by five patents issued and
several pending, with patents rights acquired from Cornell
University, Dartmouth College and Washington University. In
addition to human clinical studies, ChromaDex is actively
collaborating with numerous leading universities and research
institutes studying the health benefits of NIAGEN®. For additional
information about ChromaDex and NIAGEN®,
visit www.Chromadex.com.
Additional research and news about NR and NAD+
can be found at www.AboutNR.com.
About ChromaDex: ChromaDex leverages
its complementary business units to discover, acquire, develop and
commercialize patented and proprietary ingredient technologies that
address the dietary supplement, food, beverage, skin care and
pharmaceutical markets. In addition to our ingredient technologies
unit, we also have business units focused on natural product fine
chemicals (known as "phytochemicals"), chemistry and analytical
testing services, and product regulatory and safety consulting
(known as Spherix Consulting). As a result of our
relationships with leading universities and research institutions,
we are able to discover and license early stage, IP-backed
ingredient technologies. We then utilize our in-house chemistry,
regulatory and safety consulting business units to develop
commercially viable ingredients. Our ingredient portfolio is backed
with clinical and scientific research, as well as extensive IP
protection. Our portfolio of patented ingredient technologies
includes NIAGEN® nicotinamide
riboside; pTeroPure® pterostilbene; PURENERGY®, a
caffeine-pTeroPure® co-crystal; IMMULINA™, a spirulina
extract; and AnthOrigin™, anthocyanins derived from a
domestically-produced, water-extracted purple corn.
To learn more about ChromaDex, please
visit www.ChromaDex.com.
Forward-Looking Statements:This
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities and Exchange Act of 1934, as
amended, including statements related to results and significance
of the NIAGEN® study and the likelihood that NR will be
an effective tool in relieving chemotherapy-induced peripheral
neuropathy, whether NIAGEN® may be used in a therapeutic approach
in filling the unmet need for treatments that alleviate CIPN and
the likelihood of ChromaDex initiating a Phase I/II clinical trial
in patients with Cockayne Syndrome. Statements that are not a
description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as "expects", "anticipates", "intends", "estimates",
"plans", "potential", "possible", "probable", "believes", "seeks",
"may", "will", "should", "could" or the negative of such terms or
other similar expressions. More detailed information
about ChromaDex and the risk factors that may affect the
realization of forward-looking statements is set forth
in ChromaDex's Annual Report on Form 10-K for the fiscal
year ended January 2, 2016, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted
by ChromaDex to the SEC, copies of which may be
obtained from the SEC's website at www.sec.gov.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof,
and actual results may differ materially from those suggested by
these forward-looking statements. All forward-looking statements
are qualified in their entirety by this cautionary statement
and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof. ChromaDex provided research materials and a
portion of the grant funding as a collaborator for the study.
ChromaDex Public Relations Contact:
Breah Ostendorf, Director of Marketing
949-537-4103
breaho@chromadex.com
ChromaDex Investor Relations Contact:
Andrew Johnson, Director of Investor Relations
949-419-0288
andrewj@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2024 to May 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From May 2023 to May 2024